Advertisement OncoGenex to begin Spruce clinical trial to evaluate lung cancer agent - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

OncoGenex to begin Spruce clinical trial to evaluate lung cancer agent

OncoGenex is planning to begin the Spruce clinical trial to assess OGX-427 in combination with chemotherapy in treatment of naive patients with advanced non-squamous non-small cell lung cancer (NSCLC).

The randomized, Phase 2 study sponsored by SCRI will evaluate if the addition of OGX-427 to carboplatin and pemetrexed therapy can extend progression-free survival (PFS) outcomes.

The study primary investigator and Sarah Cannon Research Institute (SCRI) lung cancer research program director David Spigel said majority of patients do not have specific markers for targeted therapy and will still receive broad-spectrum treatments, like chemotherapy.

"There is an urgent need to improve upon outcomes for these patients," Spigel added.

"By targeting Hsp27 with an innovative therapy like OGX-427, we hope we can delay or prevent treatment resistance and extend the overall survival benefit currently provided by chemotherapy."

Around 155 patients with non-squamous NSCLC will be randimized with either OGX-427 plus carboplatin and pemetrexed therapy or placebo plus carboplatin and pemetrexed therapy.

Maintenance therapy with pemetrexed and/or OGX-427/placebo will be continued in patients until disease progression or unacceptable toxicity.

PFS is the primary objective while the additional analysis will include evaluation of tumour response rates, overall survival, safety, tolerability, and the effect of therapy on heat shock protein 27 levels.